A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

Lenalidomide is the first karyotype-selective therapeutic approved for the treatment of myelodysplastic syndromes (MDS) owing to high rates of erythroid and cytogenetic response in patients with chromosome 5q deletion [del(5q)]. Although haploinsufficiency for the RPS14 gene and others encoded withi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Wei, Sheng, Chen, Xianghong, Rocha, Kathy, Epling-Burnette, P. K., Djeu, Julie Y., Liu, Qing, Byrd, John, Sokol, Lubomir, Lawrence, Nick, Pireddu, Roberta, Dewald, Gordon, Williams, Ann, Maciejewski, Jaroslaw, List, Alan
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2009
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2722346/
https://ncbi.nlm.nih.gov/pubmed/19470455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0811267106
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars